Navigation Links
Manufacturing process developed for HIV microbicide
Date:7/3/2014

Lincoln, Neb., July 3, 2014 Scientists at the University of Nebraska-Lincoln College of Engineering's Biological Process Development Facility have successfully produced a drug compound with potential to block HIV transmission in women.

The compound features the 5P12-Rantes molecule, discovered by scientists at the Mintaka Foundation in Switzerland to block HIV transmission by preventing the virus from attaching to human cells. Mintaka has contracted with the UNL facility to develop the manufacturing method for the compound.

The UNL facility has delivered its first batch of the compound to the non-profit research organization for formulation as a vaginal cream for use in clinical trials in South America. The facility landed the $3.8 million contract in 2010 from Mintaka to develop this biological production process for the microbicide.

The successful production run also confirms that the manufacturing process developed at the BPDF is ready to be transferred to a large-scale manufacturing facility, said Scott Johnson, Good Manufacturing Practices coordinator for the UNL facility.

Robin Offord, Mintaka's executive director, said his organization is "happy with the robust nature of the process developed at BPDF."

"Properly validated GMP production is key to Mintaka's plans to empower women and girls in developing countries with a means of protection from HIV/AIDS," he said. "Already, we have successfully transferred the technology to our collaborating institution in South Africa with excellent pilot scale results."

The BPDF's role in this phase of development illustrates the complexity of bringing drugs to clinical trial, officials said.

Good Manufacturing Practices are the strict guidelines imposed by the Food and Drug Administration for the development and manufacture of all pharmaceuticals, with rigorous procedures to test and validate every aspect of the development and production process.

UNL's BPDF meets those requirements, following strict quality control standards and scrutiny for the pharmaceutical industry, including long-term environmental and water quality testing. Johnson said the facility works closely with its clients to develop processes that will produce material suitable for use in clinical trials.

"A client will present us with a gene product they want expressed," he said. "We develop and optimize that process, then scale it up and move the finalized process to our GMP facility for production."

The successful production of 5P12-Rantes was the first to be completed in the BPDF's recently commissioned GMP plant in Othmer Hall. The GMP plant was the first in the nation to be established on a university campus.


'/>"/>

Contact: Kimberly Tedrow, BPDF media contact
ktedrow2@unl.edu
402-472-1962
University of Nebraska-Lincoln
Source:Eurekalert

Related biology news :

1. Solar panel manufacturing is greener in Europe than China, study says
2. Major breakthrough in stem cell manufacturing technology
3. 3-D Printing and Additive Manufacturing: Preview issue of groundbreaking peer-reviewed journal now available
4. 3D Printing and Additive Manufacturing
5. Manufacturing a new gut to treat GI diseases
6. New technique controls dimensions of gold nanorods while manufacturing on a large scale
7. Training the future biomanufacturing workforce
8. Nanosensors could aid drug manufacturing
9. 3-D Printing and Additive Manufacturing preview issue publishing Fall 2013
10. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
11. Manufacturing crack-resistant lightweight components
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ... and clinical data from its phase 1/2 tendon repair study ... fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The clinical ... at 6 months and showed no serious adverse events related ...
(Date:3/28/2017)... ... ... Executive search firm, Slone Partners, announces the placement of ... distinguished life sciences expert with a proven track record in strategic global business ... of services related to laboratory testing and analysis for the pharmaceutical, medical device, ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a ... disease and more through a single-cell precision engineering platform, today announced it has ... in the laboratory of Dr. James Heath at the California Institute of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small cell ... with limited tumor content in a large background of normal or wild type ... need for reliable detection of low abundance somatic mutations, particularly in small specimens ...
Breaking Biology Technology: